Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting With Targets Other Than Receptors or Enzymes. Disease-Modifying Drugs. Update 2014

Journal of Alzheimer's Disease - Netherlands
doi 10.3233/jad-141206
Full Text
Abstract

Available in full text

Date
Authors
Publisher

IOS Press

Related search

Treatment of Dementias: Current Approaches and Disease Modifying Drugs

Journal of Nihon University Medical Association
2012English

P2Y Purinergic Receptors: New Targets for Analgesic and Antimigraine Drugs

Biochemical Pharmacology
BiochemistryPharmacology
2013English

Lipid Profiles in Rheumatoid Arthritis Patients Treated With Disease-Modifying Antirheumatic Drugs

Reumatologia
RheumatologyAllergyImmunology
2014English

Disease Modifying Treatments and Symptomatic Drugs for Cognitive Impairment in Multiple Sclerosis: Where Do We Stand?

Multiple Sclerosis and Demyelinating Disorders
AllergyImmunologyNeurology
2017English

Patient Preferences in the Choice of Disease Modifying Anti-Rheumatic Drugs

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Metabolism of Drugs With Inhibition of Enzymes

Journal of Drug Metabolism & Toxicology
2018English

Nanoparticle System for the Local Delivery of Disease Modifying Osteoarthritic Drugs

Osteoarthritis and Cartilage
Sports MedicineRheumatologyOrthopedicsBiomedical Engineering
2013English

The Choice Of, and the Decision to Apply, Disease Modifying Drugs.

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
1982English

Persistence With Biological Disease-Modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs

Drugs - Real World Outcomes
Pharmacology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy